2. Moreno ML, Vazquez H, Mazure R, Smecuol E, Niveloni S, Pedreira S, et al. Stratificationof bone fracture risk in patients with celiac disease. Clinical Gastroenterol Hepatol.2004;2:127–134.3. Corrarao G, Corrazza GR, Bagnardi V, Brusco G, Ciacci C, Cottone M, et al. Mortality inpatients with celiac disease and their relatives: a cohort study. Lancet. 2001;358:356–61.90
Dietary Guidelines for <strong>Celiac</strong> <strong>Disease</strong> and Implementation Cynthia Kupper, R.D., C.D.Medical nutrition therapy is the only accepted treatment for celiac disease (CD). It is astrict, gluten-free diet (GFD) for life. The GFD avoids the storage proteins from wheat, rye,barley, and hybrids of these grains, such as kamut and triticale. Historically, rice, corn, andpotato were substitutes for gluten-containing grains. Today a number of nutrient-dense grains,seeds, legumes, and nut flours offer increased variety, improved palatability, and highernutritional quality to the GFD. These grains and seeds include amaranth, buckwheat, flax, Indianrice grass, millet, tef, quinoa, and sorghum.The inclusion of oats and wheat starch in the GFD is controversial with no clear-cutguidelines for their use. Short- and long-term studies involving children and adults during thelast decade suggest oats can be included safely in the GFD. (1–3) Størsrud found the use of oatsincreased the patient’s intake of iron, dietary fiber, thiamin, and Zn. (3). However, oats in the GFDare not widely recommended in the United States and Canada, due to concerns of unacceptablyhigh levels of cross-contamination. A study by Lundin in Norway confirms that contamination ofcommercial oats can vary widely. Lundin found contamination levels between 400 ppm in commercial oats. In the sample with the highest levels, it was difficult to determinethe source of contamination, but Lundin suspects barley, not wheat, as the source. Testing of the“bottom of the bag” of the same product found contamination of
- Page 1 and 2:
NIH Consensus Development Conferenc
- Page 3 and 4:
III. What Are the Manifestations an
- Page 5 and 6:
• What is the management of celia
- Page 7 and 8:
Monday, June 28, 2004 (continued)I.
- Page 9 and 10:
Monday, June 28, 2004 (continued)II
- Page 11 and 12:
Wednesday, June 30, 2004 (continued
- Page 13 and 14:
Lisa H. RichardsonConsumer Represen
- Page 15 and 16:
Ciaran P. Kelly, M.D.Director, Celi
- Page 17 and 18:
Van S. Hubbard, M.D., Ph.D.Director
- Page 19 and 20:
AbstractsThe following are abstract
- Page 21 and 22:
susceptibility (e.g., DR17 homozygo
- Page 23 and 24:
The Pathology of Celiac DiseaseDavi
- Page 25 and 26:
In this regard, the transport pathw
- Page 27 and 28:
for the IgG-based test, while speci
- Page 29 and 30: 15. de Lecea A, Ribes-Koninckx C, P
- Page 31 and 32: Clinical Algorithm in Celiac Diseas
- Page 33 and 34: Considera diagnosisof celiac diseas
- Page 35 and 36: There are populations at particular
- Page 37 and 38: Serological Testing for Celiac Dise
- Page 39 and 40: Estimates of the sensitivity of the
- Page 41 and 42: the risk and severity of CD may als
- Page 43 and 44: What Are the Prevalence and Inciden
- Page 45 and 46: ascribed to excess menstrual loss.
- Page 47 and 48: ReferencesFamily History of Celiac
- Page 49 and 50: Carroccio A, Iannitto E, Cavataio F
- Page 51 and 52: identified by surveys or through so
- Page 53 and 54: Clinical Presentation of Celiac Dis
- Page 55 and 56: een widely reported. The question r
- Page 57 and 58: The Many Faces of Celiac Disease: C
- Page 59 and 60: References1. Green PH, Jabri B. Coe
- Page 61 and 62: Association of Celiac Disease and G
- Page 63 and 64: Does the Gluten-Free Diet Protect F
- Page 65 and 66: Skin Manifestations of Celiac Disea
- Page 67 and 68: allow a better understanding of the
- Page 69 and 70: 4. Henriksson KG, Hallert C, Walan
- Page 71 and 72: characterized, clinically-identifie
- Page 73 and 74: 10. Hoffenberg EJ, Emery LM, Barrig
- Page 75 and 76: ataxia, epilepsy with posterior cer
- Page 77 and 78: Consequences of Testing for Celiac
- Page 79: Osteoporosis/FracturesThere were 11
- Page 85 and 86: 21. Thompson T. Thiamin, riboflavin
- Page 88 and 89: In order to effectively counsel ind
- Page 90 and 91: 9. Hallert C, Granno C, Hulten S, M
- Page 92 and 93: adhered to the GFD after more than
- Page 94 and 95: Patient education, close supervisio
- Page 96: 26. Mustalahti K, Lohiniemi S, Laip
Change language